Cite
Department of Infectious Diseases Details Findings in COVID-19 (Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study)
MLA
“Department of Infectious Diseases Details Findings in COVID-19 (Safety and Efficacy of Tocilizumab in the Treatment of Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia: A Retrospective Cohort Study).” Medical Letter on the CDC & FDA, 16 Aug. 2020, p. 413. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.631992427&authtype=sso&custid=ns315887.
APA
Department of Infectious Diseases Details Findings in COVID-19 (Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study). (2020, August 16). Medical Letter on the CDC & FDA, 413.
Chicago
Medical Letter on the CDC & FDA. 2020. “Department of Infectious Diseases Details Findings in COVID-19 (Safety and Efficacy of Tocilizumab in the Treatment of Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia: A Retrospective Cohort Study),” August 16. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.631992427&authtype=sso&custid=ns315887.